All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub is an independent medical education platform, sponsored by Autolus and Biogen. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

AAD 2023

Share:

Mar 22, 2023


X post image

18 Mar 2023

CONGRESS #AAD2023 | Congrats @ErikatMcCormick on your best poster award! Penetration analysis shows improved penetration of anandamide (AEA) using nanoparticle delivery. In vitro & in vivo efficacy work suggests that encapsulated AEA may reduce inflammation in CLE lesions. #Lupus
X post image

18 Mar 2023

CONGRESS #AAD2023 | Victoria Werth @werthlab presented at the Women’s Health Therpeutic Hotline Symposium, discussing the diagnosis and management of #lupus and dermatomyositis in women. Difficulties getting drugs for CLE were highlighted as most are indicated only for #SLE
X post image

17 Mar 2023

CONGRESS #AAD2023 | @JosephMerolaMD presents ‘Rheumatology for the dermatologist’ in #CLE and #SLE highlighting treatment suggestions. #lupus
X post image

17 Mar 2023

CONGRESS #AAD2023 |@JAADjournals game changers: Alexander Egeberg presented his practice changing paper on HCQ and risk of CV events in #lupus erythematosus from Dec 2020 The study demonstrated that risk of MACE was inversely assoc with use of HCQ.

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content